JP2018507167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507167A5 JP2018507167A5 JP2017529681A JP2017529681A JP2018507167A5 JP 2018507167 A5 JP2018507167 A5 JP 2018507167A5 JP 2017529681 A JP2017529681 A JP 2017529681A JP 2017529681 A JP2017529681 A JP 2017529681A JP 2018507167 A5 JP2018507167 A5 JP 2018507167A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazol
- pyrazolo
- pyrazin
- pentan
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZWNHDUPLKJBMEF-UHFFFAOYSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n](C(C4)CC4(CO)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n](C(C4)CC4(CO)O)nc3)c[n]3nccc23)c1 ZWNHDUPLKJBMEF-UHFFFAOYSA-N 0.000 description 3
- 0 *C(*)(*)[n]1ncc(B(O*)I)c1 Chemical compound *C(*)(*)[n]1ncc(B(O*)I)c1 0.000 description 2
- IEVXFOVMPBXOPB-UHFFFAOYSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n](C4CC(CO)C4)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n](C4CC(CO)C4)nc3)c[n]3nccc23)c1 IEVXFOVMPBXOPB-UHFFFAOYSA-N 0.000 description 2
- GQMPILIYOVYDCB-CXGRPWHSSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n]([C@H](C4)C[C@@]4(C)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n]([C@H](C4)C[C@@]4(C)O)nc3)c[n]3nccc23)c1 GQMPILIYOVYDCB-CXGRPWHSSA-N 0.000 description 2
- YPBHFJWUPLVJAN-IUODEOHRSA-N C[C@H](CC(F)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound C[C@H](CC(F)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 YPBHFJWUPLVJAN-IUODEOHRSA-N 0.000 description 2
- XOLGTWQACRYHDY-UHFFFAOYSA-O CC(C)CC(C)[NH+]1N=CC(c2nc(-c3c[n](CC(CO)O)nc3)c[n]3nccc23)=C1 Chemical compound CC(C)CC(C)[NH+]1N=CC(c2nc(-c3c[n](CC(CO)O)nc3)c[n]3nccc23)=C1 XOLGTWQACRYHDY-UHFFFAOYSA-O 0.000 description 1
- XOLGTWQACRYHDY-KPMSDPLLSA-N CC(C)CC(C)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound CC(C)CC(C)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 XOLGTWQACRYHDY-KPMSDPLLSA-N 0.000 description 1
- OFCMDVUPHREYDA-UHFFFAOYSA-O CC(C)CC(C)[n]1ncc(-c2nc(C(C=N)=C[NH2+]CC(CO)O)c[n]3nccc23)c1 Chemical compound CC(C)CC(C)[n]1ncc(-c2nc(C(C=N)=C[NH2+]CC(CO)O)c[n]3nccc23)c1 OFCMDVUPHREYDA-UHFFFAOYSA-O 0.000 description 1
- SSCCJQJLIGWQAF-MBIQTGHCSA-N CC(C)[C@H](C)[n]1ncc(-c2nc(-c3c[n](CC(CO)O)nc3)c[n]3nccc23)c1 Chemical compound CC(C)[C@H](C)[n]1ncc(-c2nc(-c3c[n](CC(CO)O)nc3)c[n]3nccc23)c1 SSCCJQJLIGWQAF-MBIQTGHCSA-N 0.000 description 1
- GMFUJOMNTOHGCD-UHFFFAOYSA-O CC(CC(F)(F)F)[N+2]1N=CC(c2nc(C(C=N)=C[NH2+]CC(CO)O)c[n]3nccc23)=C1 Chemical compound CC(CC(F)(F)F)[N+2]1N=CC(c2nc(C(C=N)=C[NH2+]CC(CO)O)c[n]3nccc23)=C1 GMFUJOMNTOHGCD-UHFFFAOYSA-O 0.000 description 1
- YPBHFJWUPLVJAN-WPZCJLIBSA-N CC(CC(F)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound CC(CC(F)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 YPBHFJWUPLVJAN-WPZCJLIBSA-N 0.000 description 1
- CIJCUJJBEHAVNW-UHFFFAOYSA-N CC(CCCCC1)C1[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 Chemical compound CC(CCCCC1)C1[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 CIJCUJJBEHAVNW-UHFFFAOYSA-N 0.000 description 1
- NAGSKGCXMWXMFR-UHFFFAOYSA-N CC(CO)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 Chemical compound CC(CO)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 NAGSKGCXMWXMFR-UHFFFAOYSA-N 0.000 description 1
- KRTPHJWJOAAJKP-UHFFFAOYSA-N CC1(CCCC1)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 Chemical compound CC1(CCCC1)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 KRTPHJWJOAAJKP-UHFFFAOYSA-N 0.000 description 1
- IHZCYGIKKXIIOQ-UHFFFAOYSA-O CCC(C(C)(F)F)[NH+]1N=CC(c2nc(-c3c[n](CC(CO)O)nc3)c[n]3nccc23)=C1 Chemical compound CCC(C(C)(F)F)[NH+]1N=CC(c2nc(-c3c[n](CC(CO)O)nc3)c[n]3nccc23)=C1 IHZCYGIKKXIIOQ-UHFFFAOYSA-O 0.000 description 1
- IHZCYGIKKXIIOQ-NNJIEVJOSA-N CCC(C(C)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(C(C)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 IHZCYGIKKXIIOQ-NNJIEVJOSA-N 0.000 description 1
- ITIFSOSGXOSPND-DUSLRRAJSA-N CCC(C(C1)CC1(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(C(C1)CC1(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 ITIFSOSGXOSPND-DUSLRRAJSA-N 0.000 description 1
- BNGZGHJLRLYZLX-XPCCGILXSA-N CCC(C(F)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(C(F)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 BNGZGHJLRLYZLX-XPCCGILXSA-N 0.000 description 1
- UVCKTYRTYZYKSN-PHDNBGSHSA-O CCC(C(F)(F)F)[n]1ncc(-c2nc(/C(/C=[NH2+])=C/NCC(CO)=O)c[n]3nccc23)c1 Chemical compound CCC(C(F)(F)F)[n]1ncc(-c2nc(/C(/C=[NH2+])=C/NCC(CO)=O)c[n]3nccc23)c1 UVCKTYRTYZYKSN-PHDNBGSHSA-O 0.000 description 1
- LNWZSEFHRUUIPB-UHFFFAOYSA-N CCC(C(O)=O)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 Chemical compound CCC(C(O)=O)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 LNWZSEFHRUUIPB-UHFFFAOYSA-N 0.000 description 1
- IRPRWEJXPIFLLK-UHFFFAOYSA-N CCC(C)(CC)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 Chemical compound CCC(C)(CC)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 IRPRWEJXPIFLLK-UHFFFAOYSA-N 0.000 description 1
- NICFJHSFKDJWCZ-UHFFFAOYSA-N CCC(C1)(CN1S(C(F)(F)F)(=O)=O)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 Chemical compound CCC(C1)(CN1S(C(F)(F)F)(=O)=O)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 NICFJHSFKDJWCZ-UHFFFAOYSA-N 0.000 description 1
- RMZLLPSCCIOKBY-QSVWIEALSA-N CCC(C1CCC1)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(C1CCC1)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 RMZLLPSCCIOKBY-QSVWIEALSA-N 0.000 description 1
- JGPOTKRWWPQJSK-UHFFFAOYSA-O CCC(CC(F)(F)F)[n]1ncc(-c2nc(C(C=N)=C[NH2+]CC(CO)O)c[n]3nccc23)c1 Chemical compound CCC(CC(F)(F)F)[n]1ncc(-c2nc(C(C=N)=C[NH2+]CC(CO)O)c[n]3nccc23)c1 JGPOTKRWWPQJSK-UHFFFAOYSA-O 0.000 description 1
- CGQVSZWMAXJEFB-UHFFFAOYSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[nH]nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[nH]nc3)c[n]3nccc23)c1 CGQVSZWMAXJEFB-UHFFFAOYSA-N 0.000 description 1
- HJUVFZGONSIZFY-UHFFFAOYSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n](C(C4)CC4O)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n](C(C4)CC4O)nc3)c[n]3nccc23)c1 HJUVFZGONSIZFY-UHFFFAOYSA-N 0.000 description 1
- OANLOJFGMDFXLE-UHFFFAOYSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n](C(CO)CO)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n](C(CO)CO)nc3)c[n]3nccc23)c1 OANLOJFGMDFXLE-UHFFFAOYSA-N 0.000 description 1
- NJJAFIJJCFMWSU-UHFFFAOYSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n](CCCO)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n](CCCO)nc3)c[n]3nccc23)c1 NJJAFIJJCFMWSU-UHFFFAOYSA-N 0.000 description 1
- KITCYDCXSZDXLF-UHFFFAOYSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n](CCN(CCNC4)C4=O)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n](CCN(CCNC4)C4=O)nc3)c[n]3nccc23)c1 KITCYDCXSZDXLF-UHFFFAOYSA-N 0.000 description 1
- UYDZAZNDTNXIDX-OAHLLOKOSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n](C[C@@H](C)CO)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n](C[C@@H](C)CO)nc3)c[n]3nccc23)c1 UYDZAZNDTNXIDX-OAHLLOKOSA-N 0.000 description 1
- BIQLFOVHGXFGRI-GOSISDBHSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n](C[C@@H](CCO)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n](C[C@@H](CCO)O)nc3)c[n]3nccc23)c1 BIQLFOVHGXFGRI-GOSISDBHSA-N 0.000 description 1
- UYDZAZNDTNXIDX-HNNXBMFYSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n](C[C@H](C)CO)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n](C[C@H](C)CO)nc3)c[n]3nccc23)c1 UYDZAZNDTNXIDX-HNNXBMFYSA-N 0.000 description 1
- BIQLFOVHGXFGRI-SFHVURJKSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n](C[C@H](CCO)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n](C[C@H](CCO)O)nc3)c[n]3nccc23)c1 BIQLFOVHGXFGRI-SFHVURJKSA-N 0.000 description 1
- ZWNHDUPLKJBMEF-LBZQVFOQSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n]([C@H](C4)C[C@]4(CO)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n]([C@H](C4)C[C@]4(CO)O)nc3)c[n]3nccc23)c1 ZWNHDUPLKJBMEF-LBZQVFOQSA-N 0.000 description 1
- QUUKMKOJWSAHRW-FIWHBWSRSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n]([C@H](COC4)C4O)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n]([C@H](COC4)C4O)nc3)c[n]3nccc23)c1 QUUKMKOJWSAHRW-FIWHBWSRSA-N 0.000 description 1
- PRKDQOTWBOKRQZ-UHFFFAOYSA-O CCC(CC)[n]1ncc(-c2nc(C(C=N)=C[NH2+]CCN3CCC(CO)CC3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(C(C=N)=C[NH2+]CCN3CCC(CO)CC3)c[n]3nccc23)c1 PRKDQOTWBOKRQZ-UHFFFAOYSA-O 0.000 description 1
- PBBVBJNUBYULHP-UHFFFAOYSA-N CCC(CCO)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 Chemical compound CCC(CCO)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 PBBVBJNUBYULHP-UHFFFAOYSA-N 0.000 description 1
- NGAAOEYVYQJXJR-UHFFFAOYSA-N CCC(CO)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 Chemical compound CCC(CO)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 NGAAOEYVYQJXJR-UHFFFAOYSA-N 0.000 description 1
- PSDYYKIZXFXLFY-DNAVFNFUSA-O CCC[C@@H](C)[n]1ncc(-c2nc(/C(/C=[NH2+])=C/NC[C@@H](CO)O)c[n]3nccc23)c1 Chemical compound CCC[C@@H](C)[n]1ncc(-c2nc(/C(/C=[NH2+])=C/NC[C@@H](CO)O)c[n]3nccc23)c1 PSDYYKIZXFXLFY-DNAVFNFUSA-O 0.000 description 1
- PSDYYKIZXFXLFY-UVDRRPMQSA-O CCC[C@@H](C)[n]1ncc(-c2nc(/C(/C=[NH2+])=C/NC[C@H](CO)O)c[n]3nccc23)c1 Chemical compound CCC[C@@H](C)[n]1ncc(-c2nc(/C(/C=[NH2+])=C/NC[C@H](CO)O)c[n]3nccc23)c1 PSDYYKIZXFXLFY-UVDRRPMQSA-O 0.000 description 1
- XENRQMHKPAIYOY-UHFFFAOYSA-N CCOC(C)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 Chemical compound CCOC(C)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 XENRQMHKPAIYOY-UHFFFAOYSA-N 0.000 description 1
- QCMKOFSIVHBTCV-JERBSLHSSA-N CC[C@@H](C(C)(F)F)N(/C=C(\C)/c1nc(-c2c[n](C[C@H](CO)O)nc2)c[n]2nccc12)N=C Chemical compound CC[C@@H](C(C)(F)F)N(/C=C(\C)/c1nc(-c2c[n](C[C@H](CO)O)nc2)c[n]2nccc12)N=C QCMKOFSIVHBTCV-JERBSLHSSA-N 0.000 description 1
- IHZCYGIKKXIIOQ-QAPCUYQASA-N CC[C@@H](C(C)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound CC[C@@H](C(C)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 IHZCYGIKKXIIOQ-QAPCUYQASA-N 0.000 description 1
- RMZLLPSCCIOKBY-QUCCMNQESA-N CC[C@@H](C1CCC1)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound CC[C@@H](C1CCC1)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 RMZLLPSCCIOKBY-QUCCMNQESA-N 0.000 description 1
- VHBISBSNGUVGTR-UHFFFAOYSA-N C[n]1ncc(-c2c[n]3nccc3c(-c3c[n](C(CCC4)C4O)nc3)n2)c1 Chemical compound C[n]1ncc(-c2c[n]3nccc3c(-c3c[n](C(CCC4)C4O)nc3)n2)c1 VHBISBSNGUVGTR-UHFFFAOYSA-N 0.000 description 1
- OLPLCLUQAIDUNC-UHFFFAOYSA-N C[n]1ncc(-c2c[n]3nccc3c(-c3c[n](C4C(CO)CCC4)nc3)n2)c1 Chemical compound C[n]1ncc(-c2c[n]3nccc3c(-c3c[n](C4C(CO)CCC4)nc3)n2)c1 OLPLCLUQAIDUNC-UHFFFAOYSA-N 0.000 description 1
- OUPNAKMUTDMSBJ-UHFFFAOYSA-N C[n]1ncc(-c2c[n]3nccc3c(-c3c[n](C4CCCCCC4)nc3)n2)c1 Chemical compound C[n]1ncc(-c2c[n]3nccc3c(-c3c[n](C4CCCCCC4)nc3)n2)c1 OUPNAKMUTDMSBJ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088068P | 2014-12-05 | 2014-12-05 | |
| US62/088,068 | 2014-12-05 | ||
| PCT/US2015/064062 WO2016090285A1 (en) | 2014-12-05 | 2015-12-04 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019223760A Division JP2020055859A (ja) | 2014-12-05 | 2019-12-11 | ヤヌスキナーゼ阻害薬としての４，６−置換−ピラゾロ［１，５−ａ］ピラジン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507167A JP2018507167A (ja) | 2018-03-15 |
| JP2018507167A5 true JP2018507167A5 (enExample) | 2019-01-24 |
| JP6641373B2 JP6641373B2 (ja) | 2020-02-05 |
Family
ID=55069089
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529681A Expired - Fee Related JP6641373B2 (ja) | 2014-12-05 | 2015-12-04 | ヤヌスキナーゼ阻害薬としての４，６−置換−ピラゾロ［１，５−ａ］ピラジン |
| JP2019223760A Pending JP2020055859A (ja) | 2014-12-05 | 2019-12-11 | ヤヌスキナーゼ阻害薬としての４，６−置換−ピラゾロ［１，５−ａ］ピラジン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019223760A Pending JP2020055859A (ja) | 2014-12-05 | 2019-12-11 | ヤヌスキナーゼ阻害薬としての４，６−置換−ピラゾロ［１，５−ａ］ピラジン |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10189845B2 (enExample) |
| EP (2) | EP3878451A1 (enExample) |
| JP (2) | JP6641373B2 (enExample) |
| KR (1) | KR20170090476A (enExample) |
| CN (1) | CN107278203B (enExample) |
| AU (1) | AU2015357585B2 (enExample) |
| BR (1) | BR112017011798A2 (enExample) |
| CA (1) | CA2969709A1 (enExample) |
| CL (1) | CL2017001422A1 (enExample) |
| CO (1) | CO2017006674A2 (enExample) |
| CR (1) | CR20170309A (enExample) |
| DK (1) | DK3227297T3 (enExample) |
| ES (1) | ES2865483T3 (enExample) |
| HR (1) | HRP20210501T1 (enExample) |
| HU (1) | HUE054371T2 (enExample) |
| IL (1) | IL252656A0 (enExample) |
| MX (1) | MX386316B (enExample) |
| MY (1) | MY191016A (enExample) |
| PH (1) | PH12017501032A1 (enExample) |
| PL (1) | PL3227297T3 (enExample) |
| PT (1) | PT3227297T (enExample) |
| RS (1) | RS61693B1 (enExample) |
| RU (2) | RU2742938C2 (enExample) |
| SG (1) | SG11201704542SA (enExample) |
| SI (1) | SI3227297T1 (enExample) |
| TW (1) | TWI725004B (enExample) |
| UA (1) | UA120065C2 (enExample) |
| WO (1) | WO2016090285A1 (enExample) |
| ZA (1) | ZA201704494B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170090476A (ko) | 2014-12-05 | 2017-08-07 | 어레이 바이오파마 인크. | 야누스 키나제 저해제로서의 4,6-치환된-피라졸로[1,5-a]피라진 |
| MX383747B (es) | 2016-02-24 | 2025-03-14 | Pfizer | Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de quinasas janus (jak) |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| PT3472153T (pt) | 2016-06-16 | 2021-12-31 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| JP6888101B2 (ja) * | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| WO2018217946A1 (en) * | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| WO2019034973A1 (en) | 2017-08-14 | 2019-02-21 | Pfizer Inc. | PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| PL3954689T3 (pl) * | 2019-04-12 | 2024-08-05 | Primegene (Beijing) Co., Ltd. | Związki pochodne pirazolopirazyny, kompozycja farmaceutyczna i ich zastosowanie |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| CN113150012B (zh) * | 2020-01-22 | 2023-03-24 | 浙江海正药业股份有限公司 | 吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途 |
| BR112022020020A2 (pt) | 2020-04-04 | 2022-11-22 | Pfizer | Métodos de tratamento da doença do coronavírus 2019 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| AU2022387652B2 (en) * | 2021-11-12 | 2025-10-16 | Cms Research & Development Pte. Ltd. | Pyrazolo fused ring compound and use thereof |
| EP4711367A1 (en) * | 2023-05-12 | 2026-03-18 | CMS Research & Development Pte. Ltd. | Pyrazolopyrazine compound and method for preparing crystal form thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5682799A (en) | 1998-08-21 | 2000-03-14 | Parker Hughes Institute | Quinazoline derivatives |
| DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| EP2516434B1 (en) | 2009-12-23 | 2015-05-27 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
| CA2787714C (en) * | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
| UY33213A (es) * | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| US20110241987A1 (en) * | 2010-04-01 | 2011-10-06 | Smart Technologies Ulc | Interactive input system and information input method therefor |
| KR20130094710A (ko) * | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘 |
| SG11201401342VA (en) * | 2011-10-12 | 2014-09-26 | Array Biopharma Inc | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| HRP20160908T1 (hr) * | 2012-03-28 | 2016-09-23 | Merck Patent Gmbh | Biciklički derivati pirazinona |
| KR20170090476A (ko) | 2014-12-05 | 2017-08-07 | 어레이 바이오파마 인크. | 야누스 키나제 저해제로서의 4,6-치환된-피라졸로[1,5-a]피라진 |
-
2015
- 2015-12-04 KR KR1020177018122A patent/KR20170090476A/ko not_active Withdrawn
- 2015-12-04 RU RU2017123387A patent/RU2742938C2/ru active
- 2015-12-04 US US15/532,937 patent/US10189845B2/en active Active
- 2015-12-04 HR HRP20210501TT patent/HRP20210501T1/hr unknown
- 2015-12-04 EP EP21152373.3A patent/EP3878451A1/en not_active Withdrawn
- 2015-12-04 UA UAA201707008A patent/UA120065C2/uk unknown
- 2015-12-04 PL PL15819933T patent/PL3227297T3/pl unknown
- 2015-12-04 RU RU2021102805A patent/RU2021102805A/ru unknown
- 2015-12-04 PT PT158199331T patent/PT3227297T/pt unknown
- 2015-12-04 MY MYPI2017702034A patent/MY191016A/en unknown
- 2015-12-04 EP EP15819933.1A patent/EP3227297B1/en active Active
- 2015-12-04 WO PCT/US2015/064062 patent/WO2016090285A1/en not_active Ceased
- 2015-12-04 MX MX2017007284A patent/MX386316B/es unknown
- 2015-12-04 ES ES15819933T patent/ES2865483T3/es active Active
- 2015-12-04 CR CR20170309A patent/CR20170309A/es unknown
- 2015-12-04 HU HUE15819933A patent/HUE054371T2/hu unknown
- 2015-12-04 SG SG11201704542SA patent/SG11201704542SA/en unknown
- 2015-12-04 BR BR112017011798A patent/BR112017011798A2/pt not_active IP Right Cessation
- 2015-12-04 AU AU2015357585A patent/AU2015357585B2/en not_active Ceased
- 2015-12-04 RS RS20210415A patent/RS61693B1/sr unknown
- 2015-12-04 DK DK15819933.1T patent/DK3227297T3/da active
- 2015-12-04 CA CA2969709A patent/CA2969709A1/en not_active Abandoned
- 2015-12-04 JP JP2017529681A patent/JP6641373B2/ja not_active Expired - Fee Related
- 2015-12-04 CN CN201580066136.5A patent/CN107278203B/zh not_active Expired - Fee Related
- 2015-12-04 SI SI201531544T patent/SI3227297T1/sl unknown
- 2015-12-04 TW TW104140878A patent/TWI725004B/zh not_active IP Right Cessation
-
2017
- 2017-06-02 PH PH12017501032A patent/PH12017501032A1/en unknown
- 2017-06-04 IL IL252656A patent/IL252656A0/en active IP Right Grant
- 2017-06-05 CL CL2017001422A patent/CL2017001422A1/es unknown
- 2017-06-30 CO CONC2017/0006674A patent/CO2017006674A2/es unknown
- 2017-07-03 ZA ZA2017/04494A patent/ZA201704494B/en unknown
-
2018
- 2018-12-06 US US16/212,493 patent/US10730880B2/en active Active
-
2019
- 2019-12-11 JP JP2019223760A patent/JP2020055859A/ja active Pending
-
2020
- 2020-06-02 US US16/890,663 patent/US11028093B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11028093B2 (en) | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | |
| JP5667684B2 (ja) | 関節炎の治療方法 | |
| ES2947446T3 (es) | Compuestos inhibidores de RIP1 y métodos para fabricar y usar los mismos | |
| EP3022202B1 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| US12365668B2 (en) | Aminopyrazine diol compounds as PI3K-y inhibitors | |
| JP5788507B2 (ja) | 置換３−フェニル−１，２，４−オキサジアゾール化合物 | |
| CN111902141A (zh) | 用于ikaros降解的羟脑苷脂结合剂 | |
| IL267215B (en) | Imidazopyrrolopyridine as inhibitors of the jak family of kinases | |
| BG107236A (bg) | ПИРОЛО[2,3-d] ПИРИМИДИНОВИ СЪЕДИНЕНИЯ КАТО ИМУНОДЕПРЕСИВНИ СРЕДСТВА | |
| TW201840567A (zh) | 吡咯并[1,2-b]嗒𠯤衍生物 | |
| NZ518884A (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| CA2904797A1 (en) | Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer | |
| US20130096149A1 (en) | Heteroaryl compounds and compositions as protein kinase inhibitors | |
| JP2023525762A5 (enExample) | ||
| JP2008069149A (ja) | リウマチ様関節炎のための併用療法 | |
| TWI727392B (zh) | 噻二唑irak4抑制劑 | |
| US20210198251A1 (en) | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT | |
| US20160122336A1 (en) | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | |
| JP2024542881A (ja) | Ｋｖ７．２阻害剤としての新規ヘテロアリール－尿素化合物 | |
| US12528786B2 (en) | Plasma kallikrein inhibitors | |
| JP2019529453A (ja) | 腱及び／又は靭帯損傷に使用するためのインダゾール化合物 | |
| TW202302113A (zh) | 用於治療肉瘤之化合物 | |
| US20250059175A1 (en) | Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals | |
| JP7209415B2 (ja) | ピラゾロピリミジン化合物、医薬組成物、及びその使用 | |
| HK1238236B (en) | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors |